ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 4, 2024, at 4:30 p.m. ET at the Encore Boston Harbor Hotel in Everett, Massachusetts. Investo ...

Supernus Pharmaceuticals (SUPN) closed the last trading session at $31.48, gaining 10.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $40.50 indicates a 28.7% upside potential. The average comprises four short-term price targets ranging from a low of $38 to a high of $43, with a standard deviation of $2.08. While the lowest estimate indicates an increase of 20.7% from the curren ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Stacy Ku - TD Cowen Annabel Samimy - Stifel Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, ...

For the quarter ended June 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $168.33 million, up 24.2% over the same period last year. EPS came in at $0.36, compared to -$0.02 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $148.8 million, representing a surprise of +13.12%. The company delivered an EPS surprise of -2.70%, with the consensus EPS estimate being $0.37. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.36 per share, missing the Zacks Consensus Estimate of $0.37 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.70%. A quarter ago, it was expected that this drugmaker would post earnings of $0.39 per share when it actually produced break-even earnings, delivering a surprise of -100%. Over the last four quarters, th ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Rockville MD | --- | |----------| | | | | | | | Employer | | No.) | | | | | Commission File Number: 001-35518 SUPERNUS PHARMACEUTICALS, INC. ...

Exhibit 99.1 Supernus Announces Second Quarter 2024 Financial Results ® • Net sales of Qelbree increased 92% in the second quarter of 2024, compared to the same period in 2023. ◦ $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. • Net sales of GOCOVRI increased 10% in the second quarter of 2024, compared to the same period in 2023. ® ◦ $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. • ...

Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively. Net sales of GOCOVRI® increased 10% in the second quarter of 2024, compared to the same period in 2023. $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively. Total revenues were $168.3 million in the second quarter of 2024, an increase of ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease (PD). Supernus believes it has addressed the U.S. Food and Drug Administrat ...